



JC19 Rec'd PCT/PTO 17 MAY 2001 #6

PATENT
ATTORNEY DOCKET NO. 50059/007002

Certificate of Mailing: Date of Deposit: May 15, 2001

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Susan M. Barry

Printed name of person mailing correspondence

Susan M. Barry

Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Lee Nadler et al.	Art Unit:	Not Yet Assigned
Serial No.:	09/830,400	Examiner:	Not Yet Assigned
Filed:	April 25, 2001	Customer No.:	21559
Title:	Cancer Immunotherapy and Diagnosis Using Universal Tumor Associated Antigens, Such as the Telomerase Catalytic Subunit (hTERT), and Methods for Identifying Universal Tumor Associated Antigens		

Assistant Commissioner For Patents
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed. Copies of search reports from a corresponding PCT application are also enclosed.

Submission of this statement is not a representation that a search has been made, nor is information included in this statement an admission that the information is material to patentability.

This statement is being filed within three months of the filing date of the application. If there are any other charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: May 15, 2001

Susan M. Michaud

Susan M. Michaud, Ph.D.

Reg. No. 42,885

Clark & Elbing LLP
176 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045



21559

PATENT TRADEMARK OFFICE

● (四) 项目法人(建设单位) 项目法人(建设单位) 项目法人(建设单位) 项目法人(建设单位) 项目法人(建设单位)

\\Ntserver\documents\50059\50059.007002 Information Disclosure Statement.wpd

Sheet 1 of 1

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No.	50059/007002	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. §1.98(b))				Serial No.	09/830,400	
				Applicant	Lee Nadler et al.	
				Filing Date	April 25, 2001	
				Group	Not Yet Assigned	
				IDS Filed	May 15, 2001	
				Customer No.	21559	
U.S. PATENTS						
Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
	5,679,647	10/21/97	Carson et al.			
	5,747,317	05/05/98	Cao			
	5,770,422	06/23/98	Collins			
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
	Bohm et al., "Identification of HLA-A2-Restricted Epitopes of the Tumor-Associated Antigen MUC2 Recognized by Human Cytotoxic T Cells," <i>International J. of Cancer</i> 75:688-693 (1998).					
	Brunette et al., "Immunotherapy (Cancer): "Tumor Antigen Specific Immunotherapy of Cancer: Peptide and Gene Based Modification of Dendritic Cells as Antigen Presenting Cells," <i>Cancer Biotechnology Weekly</i> p16 (1996).					
	Celis et al., "Identification of Potential CTL Epitopes of Tumor-Associated Antigen MAGE-1 for Five Common HLA-A Alleles," <i>Molecular Immunology</i> 31:1423-1430 (1994).					
	Herlyn et al., "Epitope- and Antigen-Specific Cancer Vaccines," <i>International Review of Immunology</i> 7:245-257 (1991).					
EXAMINER				DATE CONSIDERED		
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						



21559

PATENT TRADEMARK OFFICE

1 000000 000000 000000 000000